79 related articles for article (PubMed ID: 28757314)
21. Targeted next-generation sequencing detects a high frequency of potentially actionable mutations in metastatic breast cancers.
Muller KE; Marotti JD; de Abreu FB; Peterson JD; Miller TW; Chamberlin MD; Tsongalis GJ; Tafe LJ
Exp Mol Pathol; 2016 Jun; 100(3):421-5. PubMed ID: 27095739
[TBL] [Abstract][Full Text] [Related]
22. Young investigator challenge: Can the Ion AmpliSeq Cancer Hotspot Panel v2 be used for next-generation sequencing of thyroid FNA samples?
Bellevicine C; Sgariglia R; Malapelle U; Vigliar E; Nacchio M; Ciancia G; Eszlinger M; Paschke R; Troncone G
Cancer Cytopathol; 2016 Nov; 124(11):776-784. PubMed ID: 27717198
[TBL] [Abstract][Full Text] [Related]
23. Targeted Next-Generation Sequencing Analysis of a Pendred Syndrome-Associated Thyroid Carcinoma.
Tong GX; Chang Q; Hamele-Bena D; Carew J; Hoffman RS; Nikiforova MN; Nikiforov YE
Endocr Pathol; 2016 Mar; 27(1):70-5. PubMed ID: 26744121
[TBL] [Abstract][Full Text] [Related]
24. Genetic profiling of thymic carcinoma using targeted next-generation sequencing.
Shitara M; Okuda K; Suzuki A; Tatematsu T; Hikosaka Y; Moriyama S; Sasaki H; Fujii Y; Yano M
Lung Cancer; 2014 Nov; 86(2):174-9. PubMed ID: 25249426
[TBL] [Abstract][Full Text] [Related]
25. Next-generation sequencing in thyroid cancer.
Cha YJ; Koo JS
J Transl Med; 2016 Nov; 14(1):322. PubMed ID: 27871285
[TBL] [Abstract][Full Text] [Related]
26. Next-generation sequencing in thyroid cancers: do targetable alterations lead to a therapeutic advantage?: A multicenter experience.
Moore A; Bar Y; Maurice-Dror C; Finkel I; Goldvaser H; Dudnik E; Goldstein DA; Gordon N; Billan S; Gutfeld O; Wolf I; Popovtzer A
Medicine (Baltimore); 2021 Jun; 100(25):e26388. PubMed ID: 34160418
[TBL] [Abstract][Full Text] [Related]
27. Non-invasive detection of somatic mutations using next-generation sequencing in primary central nervous system lymphoma.
Fontanilles M; Marguet F; Bohers É; Viailly PJ; Dubois S; Bertrand P; Camus V; Mareschal S; Ruminy P; Maingonnat C; Lepretre S; Veresezan EL; Derrey S; Tilly H; Picquenot JM; Laquerrière A; Jardin F
Oncotarget; 2017 Jul; 8(29):48157-48168. PubMed ID: 28636991
[TBL] [Abstract][Full Text] [Related]
28. Validation of an Ion Torrent Sequencing Platform for the Detection of Gene Mutations in Biopsy Specimens from Patients with Non-Small-Cell Lung Cancer.
Fujita S; Masago K; Takeshita J; Okuda C; Otsuka K; Hata A; Kaji R; Katakami N; Hirata Y
PLoS One; 2015; 10(6):e0130219. PubMed ID: 26076009
[TBL] [Abstract][Full Text] [Related]
29. Molecular Pathology of Anaplastic Thyroid Carcinomas: A Retrospective Study of 144 Cases.
Bonhomme B; Godbert Y; Perot G; Al Ghuzlan A; Bardet S; Belleannée G; Crinière L; Do Cao C; Fouilloux G; Guyetant S; Kelly A; Leboulleux S; Buffet C; Leteurtre E; Michels JJ; Tissier F; Toubert ME; Wassef M; Pinard C; Hostein I; Soubeyran I
Thyroid; 2017 May; 27(5):682-692. PubMed ID: 28351340
[TBL] [Abstract][Full Text] [Related]
30. BRAF mutations in an Italian cohort of thyroid cancers.
Fugazzola L; Mannavola D; Cirello V; Vannucchi G; Muzza M; Vicentini L; Beck-Peccoz P
Clin Endocrinol (Oxf); 2004 Aug; 61(2):239-43. PubMed ID: 15272920
[TBL] [Abstract][Full Text] [Related]
31. Targeted next-generation sequencing for TP53, RAS, BRAF, ALK and NF1 mutations in anaplastic thyroid cancer.
Latteyer S; Tiedje V; König K; Ting S; Heukamp LC; Meder L; Schmid KW; Führer D; Moeller LC
Endocrine; 2016 Dec; 54(3):733-741. PubMed ID: 27696251
[TBL] [Abstract][Full Text] [Related]
32. Centralized molecular testing for oncogenic gene mutations complements the local cytopathologic diagnosis of thyroid nodules.
Beaudenon-Huibregtse S; Alexander EK; Guttler RB; Hershman JM; Babu V; Blevins TC; Moore P; Andruss B; Labourier E
Thyroid; 2014 Oct; 24(10):1479-87. PubMed ID: 24811481
[TBL] [Abstract][Full Text] [Related]
33. TERT promoter mutations in thyroid cancer: a report from a Middle Eastern population.
Qasem E; Murugan AK; Al-Hindi H; Xing M; Almohanna M; Alswailem M; Alzahrani AS
Endocr Relat Cancer; 2015 Dec; 22(6):901-8. PubMed ID: 26354077
[TBL] [Abstract][Full Text] [Related]
34. Complementary utility of targeted next-generation sequencing and immunohistochemistry panels as a screening platform to select targeted therapy for advanced gastric cancer.
Kim HS; Lee H; Shin SJ; Beom SH; Jung M; Bae S; Lee EY; Park KH; Choi YY; Son T; Kim HI; Cheong JH; Hyung WJ; Park JC; Shin SK; Lee SK; Lee YC; Koom WS; Lim JS; Chung HC; Noh SH; Rha SY; Kim H; Paik S
Oncotarget; 2017 Jun; 8(24):38389-38398. PubMed ID: 28418920
[TBL] [Abstract][Full Text] [Related]
35. Versatile ion S5XL sequencer for targeted next generation sequencing of solid tumors in a clinical laboratory.
Mehrotra M; Duose DY; Singh RR; Barkoh BA; Manekia J; Harmon MA; Patel KP; Routbort MJ; Medeiros LJ; Wistuba II; Luthra R
PLoS One; 2017; 12(8):e0181968. PubMed ID: 28767674
[TBL] [Abstract][Full Text] [Related]
36. Next-generation sequencing of tyrosine kinase inhibitor-resistant non-small-cell lung cancers in patients harboring epidermal growth factor-activating mutations.
Masago K; Fujita S; Muraki M; Hata A; Okuda C; Otsuka K; Kaji R; Takeshita J; Kato R; Katakami N; Hirata Y
BMC Cancer; 2015 Nov; 15():908. PubMed ID: 26572169
[TBL] [Abstract][Full Text] [Related]
37. A rapid and sensitive enzymatic method for epidermal growth factor receptor mutation screening.
Jänne PA; Borras AM; Kuang Y; Rogers AM; Joshi VA; Liyanage H; Lindeman N; Lee JC; Halmos B; Maher EA; Distel RJ; Meyerson M; Johnson BE
Clin Cancer Res; 2006 Feb; 12(3 Pt 1):751-8. PubMed ID: 16467085
[TBL] [Abstract][Full Text] [Related]
38. [Detection of pathogenic mutations in Marfan syndrome by targeted next-generation semiconductor sequencing].
Lu C; Wu W; Xiao J; Meng Y; Zhang S; Zhang X
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2013 Jun; 30(3):301-4. PubMed ID: 23744319
[TBL] [Abstract][Full Text] [Related]
39. Detection of BRAFV600E mutation on fine needle aspiration specimens of thyroid nodule refines cyto-pathology diagnosis, especially in BRAF600E mutation-prevalent area.
Chung KW; Yang SK; Lee GK; Kim EY; Kwon S; Lee SH; Park DJ; Lee HS; Cho BY; Lee ES; Kim SW
Clin Endocrinol (Oxf); 2006 Nov; 65(5):660-6. PubMed ID: 17054470
[TBL] [Abstract][Full Text] [Related]
40. From nodule to differentiated thyroid carcinoma: contributions of molecular analysis in 2012.
Albarel F; Conte-Devolx B; Oliver C
Ann Endocrinol (Paris); 2012 Jun; 73(3):155-64. PubMed ID: 22503804
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
